February 15th, 2021 | 10:00 CET
Linde, Royal Helium, Siemens Healthineers: Which stocks are stepping on the gas?
Table of contents:
"[...] We expect the first three wells to be drilled, cased, completed and tested by the second week of March [...]" Andrew Davidson, CEO, Royal Helium Limited
At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.
Linde on the right track
Whenever gases are needed in the metalworking industry, the chemical industry, medicine or even by food manufacturers, the specialists at Linde are the first port of call. Originally started more than one hundred years ago as a company for ice machines, Linde is now valued at EUR 114 billion on the stock exchange. The Group's latest figures were positive: although sales fell by 5.6% after nine months of the fiscal year, profits still rose slightly by 0.3%. As the market had also expected a crisis result for Linde, the figures were well received.
Investors are hoping that a comeback of the global economy after the pandemic will lead to Linde also taking more money for its products. In addition to gases, Linde is also active as a hydrogen producer. To maintain this market position in the future, further innovations, also in the direction of ESG, are necessary - the competition does not sleep. As Linde is in a restructuring phase, the outcome of which is not yet clear, investors should be cautious when entering the market. However, the latest interim results point in the right direction.
Royal Helium: The share for hot weeks
The latest news from the Canadian helium Company Royal Helium also point in the right direction. The Company recently announced that it had completed the second of three wells for the noble gas, with production tests to follow. Initially, the Company had announced that it would have completed all work in about two weeks. However, Royal Helium points out that the production tests are likely to take longer due to a large number of test sections. In the market, Royal Helium's stock is taking a breather. After the Company announced the current drilling in mid-January, the share price rose rapidly from less than EUR 0.30 to over EUR 0.50. In the meantime, the value has found a bottom just below EUR 0.45.
Helium is a critical element due to its use in medical technology and the manufacture of computer chips. It is not recyclable and typically an expensive raw material. Royal Helium operates with an experienced team in a classic production area in the Canadian province of Saskatchewan, which is characterized by high helium concentrations and good conditions for commodity companies. The share is a highly speculative investment, as investors are currently focusing solely on the current drilling program results. Investors looking for a dynamic share may want to add the stock in a calm market phase.
Siemens Healthineers: Uncertainty ahead
At first glance, the Siemens Healthineers share also looks attractive. The Siemens spin-off covers the medical division, primarily imaging equipment, such as X-ray machines or even computer tomographs. It also includes gases. Looking at the figures for the first nine months of the fiscal year, it quickly becomes clear why Siemens has put its subsidiary on its own feet: Sales fell and profits slipped as part of the nine-month figures. In 2020, the Company bought cancer specialist Varian. This measure was financed with a capital increase.
Further capital measures are conceivable in the medium term. However, the latest quarterly figures have raised hopes on the market, showing a jump in profits. The Company maintained the forecast for 2021. Partly because of these promising figures, the share price rose by around 25% over three months. But will this development continue?
The trend of the past months points upwards, but the Company remains in a difficult phase. The integration of the acquisition and possible further capital measures could cause further uncertainty. For investors, the Siemens Healthineers share is not a must-have - even if the healthcare sector is fundamentally attractive. Those looking for dynamic growth would be better off investing in other stocks. An alternative for speculative investors is the share of Royal Helium.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.